Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC

Clinical trial NCT05549778 · COMPLETED

Trial details

NCT number: NCT05549778
Sponsor: Jiangnan University
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Castration-resistant Prostate Cancer

Start date: 2021-01-06
Primary completion: 2023-01-20
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.